These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 20629191)

  • 1. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
    Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
    Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
    Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
    Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
    Maeda T; Nagata K; Yoshida Y
    Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
    Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK
    Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
    Walsh S; Finn DP; Dowd E
    Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model.
    Tripanichkul W; Jaroensuppaperch EO
    Int J Neurosci; 2012 May; 122(5):263-70. PubMed ID: 22176529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
    Gomide V; Bibancos T; Chadi G
    Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat.
    Blandini F; Cova L; Armentero MT; Zennaro E; Levandis G; Bossolasco P; Calzarossa C; Mellone M; Giuseppe B; Deliliers GL; Polli E; Nappi G; Silani V
    Cell Transplant; 2010; 19(2):203-17. PubMed ID: 19906332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
    Sedaghat K; Finkelstein DI; Gundlach AL
    Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
    Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
    Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic role of glial cells in Parkinson's disease.
    Teismann P; Tieu K; Cohen O; Choi DK; Wu DC; Marks D; Vila M; Jackson-Lewis V; Przedborski S
    Mov Disord; 2003 Feb; 18(2):121-9. PubMed ID: 12539204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
    Deumens R; Blokland A; Prickaerts J
    Exp Neurol; 2002 Jun; 175(2):303-17. PubMed ID: 12061862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
    Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
    J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.